Octapharma
Octapharma
Explore linked clinical trials.14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, agammaglobulinemia, hematologic disorder, immune system disorder, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Phase 3 | 2026-09-29 | NCT07220915 | |
| Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks | Edema, Hypersensitivity, Immediate, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, immune system disorder, skin disorder, skin vascular disease, urticaria, vascular disorder | Recruiting | Phase 3 | 2026-09-29 | NCT06361537 | |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | Blood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, hematologic disorder, hereditary antithrombin deficiency, hereditary disease, inherited blood coagulation disorder, thrombophilia | Recruiting | Phase 3 | 2026-09-28 | NCT06096116 | |
| Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery | Congenital Antithrombin Deficiency | Recruiting | Phase 3 | 2026-09-28 | NCT04918173 | |
| Treatment of Hemophilia A Patients With FVIII Inhibitors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not stated | 2026-09-23 | NCT04023019 | |
| Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure | vitamin K-dependent clotting factors, combined deficiency of, type 1 | Active, not recruiting | Not stated | 2026-09-15 | NCT06429787 | |
| Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Primary Immunodeficiency Diseases, hereditary disease, immune system disorder, inborn error of immunity | Active, not recruiting | Phase 3 | 2026-08-06 | NCT04640142 | |
| Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | Phase 3 | 2026-08-05 | NCT04929236 | |
| Effectiveness and Tolerability of Eqwilate in Real-life Conditions | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, blood platelet disease, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, von Willebrand disease (hereditary or acquired) | Active, not recruiting | Not stated | 2026-07-16 | NCT04106908 | |
| Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not stated | 2026-06-02 | NCT03695978 | |
| Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 4 | 2026-05-12 | NCT05936580 | |
| Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Recruiting | Phase 4 | 2026-05-12 | NCT05935358 | |
| Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Primary Immunodeficiency Diseases, hereditary disease, immune system disorder, inborn error of immunity | Active, not recruiting | Not stated | 2026-05-08 | NCT04354129 | |
| Von Willebrand Factor in Pregnancy (VIP) Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hemorrhage, Obstetric Labor Complications, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postpartum Hemorrhage, Urogenital Diseases, Uterine Hemorrhage, blood coagulation disease, blood platelet disease, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, pregnancy disorder, puerperal disorder, von Willebrand disease (hereditary or acquired) | Recruiting | Not stated | 2025-12-18 | NCT04146376 |